AbCellera Biologics (ABCL) 44th Annual J.P. Morgan Healthcare Conference summary

Company overview and strategic evolution

• Transitioned from a technology/platform-based model to a clinical-stage company with multiple assets advancing toward late-stage development over the next 6–18 months.

• Built a global presence with 600 employees and 300,000 sq ft of facilities, including a new GMP manufacturing site in Vancouver.

• Secured over $2.1 billion in funding since inception, including $1 billion in COVID-19 royalties and $400 million in government support.

• Maintains strong liquidity with $680 million as of Q3, supporting ongoing clinical and infrastructure investments.

Pipeline progress and clinical development

• Shifted focus in September 2023 from external partnerships to internal pipeline development, now advancing four main clinical assets.

• Lead asset ABCL635, a first-in-class antibody for non-hormonal menopause symptom treatment, rapidly advanced to phase II with a key data readout expected in Q3 2025.

• ABCL575 (OX40 ligand) in phase I, with a readout anticipated by year-end; ABCL688 and ABCL386 are in IND-enabling stages targeting autoimmune and oncology indications.

• Plans to nominate an additional development candidate and initiate late-stage studies for lead programs by late 2026/early 2027.

Differentiation and market opportunity

• ABCL635 targets NK3R for menopause-related hot flashes, aiming for once-monthly subcutaneous dosing, improved safety, and higher efficacy versus oral competitors.

• Market research indicates a majority of women prefer monthly injectables over daily oral treatments for convenience.

• The addressable U.S. market includes at least 6 million women with moderate to severe symptoms, with 20% contraindicated for hormone therapy.

• Antibody approach expected to avoid liver toxicity and somnolence seen in oral NK3R antagonists, potentially enabling higher dosing and better outcomes.